|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2001
Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone
1 Karolinska Hospital, Stockholm, Sweden, 2 Mainz University Hospital, Germany, 3 Ullevål Hospital, Oslo, Norway, 4 La Fe University Hospital, Valencia, Spain, 5 Päijät-Häme Central Hospital, Lahti, Finland, 6 Beaumont Hospital, Dublin, Ireland and 7 AstraZeneca, Lund, Sweden
CORRESPONDENCE: O. Zetterström, Karolinska Sjukhuset, Allergicentrum Universitetssjukhuset, S-581 85, Linköping, Sweden.
Keywords: asthma, budesonide, formoterol, glucocorticosteroids, inhalation
Received: July 21, 2000
Accepted March 28, 2001
This study was supported by AstraZeneca, Lund, Sweden.
Budesonide/formoterol in a single inhaler was compared with budesonide alone, and with concurrent administration of budesonide and formoterol from separate inhalers, in patients with asthma, not controlled with inhaled glucocorticosteroids alone.
In this 12-week, double-blind, randomized, double-dummy study, 362 adult asthmatics (forced expiratory volume in one second 73.8% of predicted, inhaled glucocorticosteroid dose 960 µg·day–1) received single inhaler budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5 µg, two inhalations b.i.d., or corresponding treatment with budesonide, or budesonide plus formoterol via separate inhalers.
There was a greater increase in morning peak expiratory flow (PEF) with single-inhaler (35.7 L·min–1) and separate-inhaler (32.0 L·min–1) budesonide and formoterol, compared with budesonide alone (0.2 L·min–1; p<0.001, both comparisons); the effect was apparent after 1 day (p<0.001 versus budesonide, both comparisons). Similarly, evening PEF, use of rescue medication, total asthma symptom scores and percentage of symptom-free days improved more with both single inhaler and separate inhaler therapy than with budesonide alone, as did asthma control days (
It is concluded that single inhaler therapy with budesonide and formoterol is a clinically effective and well-tolerated treatment for patients with asthma that is not fully controlled by inhaled glucocorticosteroids alone.
15% more, p<0.001 versus budesonide, both comparisons, with a marked increase in the first week). All treatments were well tolerated and the adverse event profile was similar in all three treatment groups.
This article has been cited by other articles:
|
|
 |
|
  M. Wijesinghe, M. Weatherall, K. Perrin, M. Harwood, and R. Beasley Risk of mortality associated with formoterol: a systematic review and meta-analysis Eur. Respir. J., October 1, 2009; 34(4): 803 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Reddel, D. R. Taylor, E. D. Bateman, L.-P. Boulet, H. A. Boushey, W. W. Busse, T. B. Casale, P. Chanez, P. L. Enright, P. G. Gibson, et al. An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations: Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice Am. J. Respir. Crit. Care Med., July 1, 2009; 180(1): 59 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tronde, M. Gillen, L. Borgstrom, J. Lotvall, and J. Ankerst Pharmacokinetics of Budesonide and Formoterol Administered Via 1 Pressurized Metered-Dose Inhaler in Patients With Asthma and COPD J. Clin. Pharmacol., November 1, 2008; 48(11): 1300 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. F. Rabe, E. Pizzichini, B. Stallberg, S. Romero, A. M. Balanzat, T. Atienza, P. A. Lier, and C. Jorup Budesonide/Formoterol in a Single Inhaler for Maintenance and Relief in Mild-to-Moderate Asthma: A Randomized, Double-Blind Trial. Chest, February 1, 2006; 129(2): 246 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Vogelmeier, A. D'Urzo, R. Pauwels{dagger}, J. M. Merino, M. Jaspal, S. Boutet, I. Naya, and D. Price Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur. Respir. J., November 1, 2005; 26(5): 819 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Overbeek, P. G. Mulder, S. M. Baelemans, H. C. Hoogsteden, and J.-B. Prins Formoterol Added to Low-Dose Budesonide Has No Additional Antiinflammatory Effect in Asthmatic Patients Chest, September 1, 2005; 128(3): 1121 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. O'Byrne, H. Bisgaard, P. P. Godard, M. Pistolesi, M. Palmqvist, Y. Zhu, T. Ekstrom, and E. D. Bateman Budesonide/Formoterol Combination Therapy as Both Maintenance and Reliever Medication in Asthma Am. J. Respir. Crit. Care Med., January 15, 2005; 171(2): 129 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Sin, J. Man, H. Sharpe, W. Q. Gan, and S. F. P. Man Pharmacological Management to Reduce Exacerbations in Adults With Asthma: A Systematic Review and Meta-analysis JAMA, July 21, 2004; 292(3): 367 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. O'Byrne Pharmacologic Interventions to Reduce the Risk of Asthma Exacerbations Proceedings of the ATS, April 1, 2004; 1(2): 105 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jenkins Formoterol as relief medication in asthma: the jury is still out Eur. Respir. J., November 1, 2003; 22(5): 723 - 724. [Full Text] [PDF]
|
|
|
|
|
|
U. G. Lalloo, J. Malolepszy, D. Kozma, K. Krofta, J. Ankerst, B. Johansen, and N. C. Thomson Budesonide and Formoterol in a Single Inhaler Improves Asthma Control Compared With Increasing the Dose of Corticosteroid in Adults With Mild-to-Moderate Asthma Chest, May 1, 2003; 123(5): 1480 - 1487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.D. Bateman, L.F. Frith, and G.L. Braunstein Achieving guideline-based asthma control: does the patient benefit? Eur. Respir. J., September 1, 2002; 20(3): 588 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 {blacktriangledown}Seretide and {blacktriangledown}Symbicort in asthma management DTB, August 1, 2002; 40(8): 62 - 64. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |